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Zika Virology and History
Zika Virus
 Discovered in the Zika forest, Uganda 1947
 Flavivirus, single-stranded RNA
 Mosquito-borne (Aedes aegypti and 
Aedes albopictus)
 Symptoms may include fever, rash, 
conjunctivitis, and myalgia
 Most infections are asymptomatic
 Virus is detectable in serum, urine, saliva, and semen
 Recent outbreaks include Yap Island, Federated States of 
Micronesia 2007, and French Polynesia 2013-2014
Zika Virus Outbreak 2015: Western Hemisphere
 In May 2015, the Pan American Health Organization 
(PAHO) issued an alert regarding the first confirmed 
Zika virus infection in Brazil
 Reports of Guillain-Barré syndrome and pregnant 
women giving birth to babies with birth defects and 
poor pregnancy outcomes
Zika Virus Outbreak 2015
Lanciotti et al., EID 2016:
http://wwwnc.cdc.gov/eid/article/22/5/16-0065_article 
Zika Virus Epidemiology Update
Zika virus disease cases reported to ArboNET, 2015-2016 as of 
June 12, 2016
 US
– 691 travel associated cases
• 206 pregnant women
• 2 cases of GBS
• 11 cases sexual transmission
 US Territories
– 1,305 cases (~99% local transmission)
• 166 pregnant women
• 7 cases of GBS
Zika Diagnostics
CDC Trioplex rRT-PCR Assay 
 Emergency Use Authorization issued on March 17, 2016
 Detects Zika, dengue, and chikungunya in serum and 
cerebrospinal fluid
 Detects Zika in urine and amniotic fluid
 Testing is limited to qualified laboratories designated by CDC
Trioplex rRT-PCR Assay: Amendments to EUA
 External lysis protocol added (May 31, 2016)
 Increase sample input volume to increase sensitivity – data 
collection ongoing
 Include additional automated extraction platforms to 
increase throughput – plan being finalized with FDA
Focus Diagnostics Zika Virus RNA Qualitative Real-
Time RT-PCR
 Emergency Use Authorization issued on April 28, 2016
 Testing is limited to Quest Diagnostics laboratories
 Acceptable specimen: Serum
 Detects Zika only
Altona RealStar® Zika Virus RT-PCR
 Emergency Use Authorization issued on May 13, 2016
 Testing is limited to CLIA labs certified to perform high 
complexity tests
 Acceptable specimens: Serum and urine
 Detects Zika virus only
CDC Zika MAC-ELISA
 Emergency Use Authorization issued on February 26, 2016
 Testing is limited to qualified laboratories designated by CDC
 Presumptive positive, equivocal or repeated inconclusive results 
require confirmatory testing
 Acceptable specimens: Serum and cerebrospinal fluid
 Anti-Zika antibodies present in a specimen will neutralize virus
Confirmatory Antibody Testing: Plaque-Reduction 
Neutralization Test (PRNT)
Cell monolayer
Patient with Zika infection:
Plaque reduction
since virus is neutralized
Testing well 
Cell monolayer
Patient without Zika infection:
Plaque formation
Example results using 
infected patient’s serum
Zika virus free to infect cells
Neutralizing 
antibodies prevent binding 
CDC Zika MAC-ELISA: Amendments to EUA
 Integrate Zika virus-like particles (VLPs) into the Zika MAC-
ELISA assay to speed manufacturing of antigen – data under 
review by FDA
– Can be easily grown in large amounts and are non-
infectious
 Add automated robotic system to the Zika MAC-ELISA –
initial data collected
Laboratory Response Network Testing Capacity 
in the US 
 CDC Trioplex rRT-PCR
• 102 labs have received reagents (all states plus DC and PR)
• 74 have completed verification panel (39 states plus DC and PR)
 CDC Zika MAC-ELISA
• 52 labs have received reagents – 42 states, DC, and PR
• 38 laboratories have completed verification panel (32 states plus DC)
Surge Capacity for Zika Diagnostic Testing in the US
 Meeting with states with high risk for local transmission and 
developing capacity to meet potential testing demand
 Encouraging all labs to consider maximum capacity even if the 
state is not considered to be high risk
 Identifying challenges with shipping samples across state lines 
and reporting results
 Awarding $40 million to ELC grantees in August for Zika virus 
surveillance, laboratory diagnostic, and communication 
activities
Diagnostic Testing Algorithms
Collection of Urine from Symptomatic Patients
 Urine samples <14 days should be collected and tested by 
rRT-PCR along with patient-matched serum
 MMWR describing detection of Zika virus RNA in urine 
5/10/2016
 CDC Health Alert Network (HAN) Health Advisory Regarding 
Diagnostic Testing of Urine Specimens for Suspected Zika 
Virus Infection on 5/25/2016 
Serum collected < 7 days and urine collected < 14 days after symptom onset
(CSF or amniotic fluid for some tests)
Test all specimens by Trioplex rRT-PCR





















































































Algorithm for Testing Symptomatic Patients:
Serum and/or CSF collected >7 days after symptom onset
Serological testing
Serum and/or CSF specimen should be tested by:
• Zika MAC-ELISA
• a dengue IgM assay
• a chikungunya IgM assay
Any test presumptive positive, 
equivocal or inconclusive.
Report results.
Forward for confirmation by PRNT
All tests negative, no  evidence of recent 
virus infection. 
Report results.
No further testing of specimen required.
Serum tested by PRNT by CDC or CDC-designated confirmatory testing 
laboratory.
Report results.  
Combine results with results of other diagnostic tests to determine 
overall interpretation. 
NEGPOS
Algorithm for Testing Symptomatic Patients:
Women residing in an active Zika transmission area or 2-12 weeks after travel to an active Zika virus transmission area or sexual contact 
with a person confirmed to have Zika virus infection.  
Test serum specimen by the Zika MAC-ELISA




Report no evidence of recent Zika 
virus infection
Forward specimen for 
confirmation by PRNT
Serum tested by PRNT by CDC or CDC-designated confirmatory testing 
laboratory.
Report results.  
Combine results with results of other diagnostic tests to determine 
overall interpretation. 
NEGPOS
Algorithm for Testing Asymptomatic Pregnant Women:
Reporting
 Zika virus disease is a nationally notifiable condition
• ArboNET – National surveillance system for arboviral diseases 
 U.S. Pregnancy Registries
• ZAPSS – Zika Active Pregnancy Surveillance System (Puerto Rico)
• USZPR – Zika Pregnancy Registry (US patients)
Test Interpretation Guidance
Interim Guidance: Interpretation of Zika Virus 
Antibody Test Results
 4-fold difference in PRNT titer may not differentiate between anti-Zika 
virus antibodies and cross-reacting antibodies in all persons who have 
been previously infected with or vaccinated against a related flavivirus
 PRNT result interpretations have been updated to reduce the possibility of 
missing the diagnosis of either Zika or dengue virus infection
 Pregnant women with a Zika or flavivirus infection interpretation should 
be evaluated and managed for adverse pregnancy outcomes and be 
reported to the appropriate registry.
Interim Guidance: Interpretation of Zika Virus 
Antibody Test Results
Interim Guidance: Interpretation of Zika Virus 
Antibody Test Results
 A PRNT using a 90% cutoff value with a titer ≥10 against Zika virus, 
together with negative PRNTs (i.e., <10) against other flaviviruses is 
confirmatory for infection with Zika virus 
 A PRNT titer ≥10 for both Zika and dengue virus (or another flavivirus) 
provides evidence of an infection with a flavivirus but precludes 
identification of the specific infecting virus
 For specimens collected <7 days after onset of symptoms, the 
combination of a negative rRT-PCR and a PRNT titer <10 suggests that 
there was no infection with Zika virus
Questions?
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
